Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma

Daratumumab, a human immunoglobulin G1 kappa monoclonal antibody that targets CD38, is currently approved as monotherapy and in varying combinations with approved anti-myeloma regimens in both newly diagnosed multiple myeloma and relapsed refractory multiple myeloma. Originally developed for intrave...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Adv Hematol
Autors principals: Sanchez, Larysa, Richter, Joshua, Cho, Hearn Jay, Jagannath, Sundar, Madduri, Deepu, Parekh, Samir, Richard, Shambavi, Tam, Lowena, Verina, Daniel, Chari, Ajai
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2021
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7841854/
https://ncbi.nlm.nih.gov/pubmed/33613930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720987075
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars